Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma (Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer)

INTERVENTION: combination of paclitaxel and carboplatin PTX180mg/m2, day1+CBDCA AUC6.0 day1 every 21 days for 6‐9cycles combination of paclitaxel and carboplatin PTX80mg/m2 day1,8,15+CBDCA AUC6.0 day1 every 21 days for 6‐9cycles CONDITION: Patients with stageII‐IV Mullerian Carcinoma (Ovarian Epithelial,Primary Peritoneal,or Fallopian Tube Cancer) PRIMARY OUTCOME: Progression‐free Survival SECONDARY OUTCOME: Overall Suvival/Adverse event/Clinical Objective Response/Quality of life INCLUSION CRITERIA: I. Histologically confirmed stage II‐IV ovarian epithelial, primary peritoneal, or fallopian tube cancer II. No prior chemotherapy III. Age: 20 and more IV. Performance status: ECOG 0‐2 V. 1) Absolute neutrophil count at least 1,500/mm3 2) Platelet count at least 100,000/mm3 3) Bilirubin less than 1.5mg/dL 4) SGOT less than 100 IU/l 5) Serum creatinine less than 1.5mg/dL VI. Written informed consent